Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 12/20 | 0.61 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.58 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.58 |
| ▸ | GHSR | Q92847 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38662290 | 0.98 | IL23R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL30379397 | 0.98 | IL23R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL29938267 | 0.97 | IL23R (0.61) | IL23RKISS1RUTS2RGHSR | |
| SCHEMBL29938179 | 0.97 | IL23R (0.61) | IL23RKISS1RUTS2RGHSR | |
| SCHEMBL31619557 | 0.97 | IL23R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL30276251 | 0.97 | IL23R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL31514538 | 0.96 | IL23R (0.65) | IL23RKISS1RUTS2RGHSR | |
| SCHEMBL30380084 | 0.96 | IL23R (0.65) | IL23RKISS1RUTS2RGHSR | |
| SCHEMBL29408676 | 0.96 | IL23R (0.65) | IL23RKISS1RUTS2RGHSR | |
| SCHEMBL29361083 | 0.96 | IL23R (0.65) | IL23RKISS1RUTS2RGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043563-A1 | PEPTIDE TARGETING SOMATOSTATIN RECEPTOR, DRUG CONJUGATE AND USE THEREOF | 主流源生物科技(上海)有限公司 | 2025-03-06 | — | — | WO | claimed |
| US-20250345468-A1 | COMBINATION TREATMENT OF SMALL-CELL LUNG CANCER | ITM ISOTOPE TECH MUNICH SE (DE) | 2025-11-13 | — | — | US | disclosed |
| WO-2025043563-A1 | PEPTIDE TARGETING SOMATOSTATIN RECEPTOR, DRUG CONJUGATE AND USE THEREOF | 主流源生物科技(上海)有限公司 | 2025-03-06 | — | — | WO | disclosed |
| EP-4514405-A1 | COMBINATION TREATMENT OF SMALL-CELL LUNG CANCER | ITM Isotope Technologies Munich SE (DE) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023209122-A1 | COMBINATION TREATMENT OF SMALL-CELL LUNG CANCER | ITM Isotope Technologies Munich SE (DE) | 2023-11-02 | — | — | WO | disclosed |
| EP-4251213-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | ITM Solucin GmbH (DE) | 2023-10-04 | — | — | EP | disclosed |
| EP-4065176-A1 | COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER | ITM Isotope Technologies Munich SE (DE) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022111800-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | ITM SOLUCIN GMBH (DE) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022112323-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | ITM SOLUCIN GMBH (DE) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022096673-A1 | COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER | ITM Isotopen Technologien München AG (DE) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022096103-A1 | COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER | ITM Isotopen Technologien München AG (DE) | 2022-05-12 | — | — | WO | disclosed |
| EP-3965751-A1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | ITM Isotope Technologies Munich SE (DE) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345468-A1 | COMBINATION TREATMENT OF SMALL-CELL LUNG CANCER | SSTR1, SSTR3, SSTR2 | IL23R 475/4885KISS1R 115/4885UTS2R 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.